Determinants of poor 6-min walking distance in patients with COPD: the ECLIPSE cohort

Martijn A Spruit; Michael L Watkins; Lisa D Edwards; Jørgen Vestbo; Peter M A Calverley; Victor Pinto-Plata; Bartolome R Celli; Ruth Tal-Singer; Emiel F M Wouters; NN NN

doi:10.1016/j.rmed.2009.12.007

Determinants of poor 6-min walking distance in patients with COPD: the ECLIPSE cohort

Martijn A Spruit, Michael L Watkins, Lisa D Edwards, Jørgen Vestbo, Peter M A Calverley, Victor Pinto-Plata, Bartolome R Celli, Ruth Tal-Singer, Emiel F M Wouters, NN NN

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

178 Citationer (Scopus)

Abstract

Udgivelsesdato: 2010-Jun

Originalsprog	Engelsk
Tidsskrift	Respiratory Medicine
Vol/bind	104
Udgave nummer	6
Sider (fra-til)	849-57
Antal sider	8
ISSN	0954-6111
DOI	https://doi.org/10.1016/j.rmed.2009.12.007
Status	Udgivet - 2010

Bibliografisk note

Adgang til dokumentet

10.1016/j.rmed.2009.12.007

Citationsformater

@article{0d392f00a85441268f4a79134e3dadc5,

title = "Determinants of poor 6-min walking distance in patients with COPD: the ECLIPSE cohort",

abstract = "BACKGROUND: The 6-min walking test (6MWT) is widely used to assess exercise tolerance in patients with chronic obstructive pulmonary disease (COPD). Given the prognostic significance of the 6MWT, it is important to identify why some COPD patients perform poorly in terms of this outcome. We aimed to identify clinical determinants of a poor 6-min walking distance (<350 m) in patients with COPD. METHODS: 1795 individuals with a diagnosis of COPD underwent spirometry; bio-electrical impedance analysis; low-dose computed tomography scans of the chest; 6MWT; ATS-DLD co-morbidity questionnaire; Center for Epidemiologic Studies of Depression Scale; COPD-specific St Georges Respiratory Questionnaire; modified Medical Research Council (mMRC) dyspnea scale as part of the baseline assessment of the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) study. RESULTS: Patients with COPD have significant differences in performance in the 6MWT even after stratification for GOLD stages. Moreover, severe airflow limitation by GOLD stage, degree of emphysema by CT, oxygen use during/after the 6MWT, presence of depressive symptoms and moderate to severe symptoms of dyspnea (mMRC grade >/=2) are significant clinical determinants of poor 6MWD performance (<350 m). CONCLUSIONS: The determinants of poor 6MWD are complex and depend on both physical (both pulmonary and non-pulmonary factors) and psychological factors as evaluated from a large multinational cohort of well-characterised patients with clinically stable moderate to very severe COPD.",

author = "Spruit, {Martijn A} and Watkins, {Michael L} and Edwards, {Lisa D} and J{\o}rgen Vestbo and Calverley, {Peter M A} and Victor Pinto-Plata and Celli, {Bartolome R} and Ruth Tal-Singer and Wouters, {Emiel F M} and NN NN",

year = "2010",

doi = "10.1016/j.rmed.2009.12.007",

language = "English",

volume = "104",

pages = "849--57",

journal = "Respiratory Medicine",

issn = "0954-6111",

publisher = "Elsevier",

number = "6",

}

TY - JOUR

T1 - Determinants of poor 6-min walking distance in patients with COPD: the ECLIPSE cohort

AU - Spruit, Martijn A

AU - Watkins, Michael L

AU - Edwards, Lisa D

AU - Vestbo, Jørgen

AU - Calverley, Peter M A

AU - Pinto-Plata, Victor

AU - Celli, Bartolome R

AU - Tal-Singer, Ruth

AU - Wouters, Emiel F M

AU - NN, NN

PY - 2010

Y1 - 2010

N2 - BACKGROUND: The 6-min walking test (6MWT) is widely used to assess exercise tolerance in patients with chronic obstructive pulmonary disease (COPD). Given the prognostic significance of the 6MWT, it is important to identify why some COPD patients perform poorly in terms of this outcome. We aimed to identify clinical determinants of a poor 6-min walking distance (<350 m) in patients with COPD. METHODS: 1795 individuals with a diagnosis of COPD underwent spirometry; bio-electrical impedance analysis; low-dose computed tomography scans of the chest; 6MWT; ATS-DLD co-morbidity questionnaire; Center for Epidemiologic Studies of Depression Scale; COPD-specific St Georges Respiratory Questionnaire; modified Medical Research Council (mMRC) dyspnea scale as part of the baseline assessment of the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) study. RESULTS: Patients with COPD have significant differences in performance in the 6MWT even after stratification for GOLD stages. Moreover, severe airflow limitation by GOLD stage, degree of emphysema by CT, oxygen use during/after the 6MWT, presence of depressive symptoms and moderate to severe symptoms of dyspnea (mMRC grade >/=2) are significant clinical determinants of poor 6MWD performance (<350 m). CONCLUSIONS: The determinants of poor 6MWD are complex and depend on both physical (both pulmonary and non-pulmonary factors) and psychological factors as evaluated from a large multinational cohort of well-characterised patients with clinically stable moderate to very severe COPD.

AB - BACKGROUND: The 6-min walking test (6MWT) is widely used to assess exercise tolerance in patients with chronic obstructive pulmonary disease (COPD). Given the prognostic significance of the 6MWT, it is important to identify why some COPD patients perform poorly in terms of this outcome. We aimed to identify clinical determinants of a poor 6-min walking distance (<350 m) in patients with COPD. METHODS: 1795 individuals with a diagnosis of COPD underwent spirometry; bio-electrical impedance analysis; low-dose computed tomography scans of the chest; 6MWT; ATS-DLD co-morbidity questionnaire; Center for Epidemiologic Studies of Depression Scale; COPD-specific St Georges Respiratory Questionnaire; modified Medical Research Council (mMRC) dyspnea scale as part of the baseline assessment of the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) study. RESULTS: Patients with COPD have significant differences in performance in the 6MWT even after stratification for GOLD stages. Moreover, severe airflow limitation by GOLD stage, degree of emphysema by CT, oxygen use during/after the 6MWT, presence of depressive symptoms and moderate to severe symptoms of dyspnea (mMRC grade >/=2) are significant clinical determinants of poor 6MWD performance (<350 m). CONCLUSIONS: The determinants of poor 6MWD are complex and depend on both physical (both pulmonary and non-pulmonary factors) and psychological factors as evaluated from a large multinational cohort of well-characterised patients with clinically stable moderate to very severe COPD.

U2 - 10.1016/j.rmed.2009.12.007

DO - 10.1016/j.rmed.2009.12.007

M3 - Journal article

SN - 0954-6111

VL - 104

SP - 849

EP - 857

JO - Respiratory Medicine

JF - Respiratory Medicine

IS - 6

ER -